| Peter C Glassbrenner, | |
|
353 Fairmont Blvd, Rapid City, SD 57701-7350 | |
| (605) 719-1000 | |
| Not Available |
| Full Name | Peter C Glassbrenner |
|---|---|
| Gender | Male |
| Speciality | Nurse Anesthetist, Certified Registered |
| Location | 353 Fairmont Blvd, Rapid City, South Dakota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811335391 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | CR000826 (South Dakota) | Primary |
| Entity Name | Monument Health Network Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588185268 PECOS PAC ID: 5991616427 Enrollment ID: O20031111000854 |
News Archive
Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced it will be presenting data from the Phase 2 clinical trial of their lead drug candidate for postmenopausal symptoms, Menerba, to the international community at the 13th Annual World Congress on Menopause in Rome, Italy on June 11, 2011.
Sigma-Aldrich (Nasdaq: SIAL) announced today that it has entered into a worldwide licensing agreement with Australia's Commonwealth Scientific and Industrial Research Organization (CSIRO) to manufacture and sell Reversible Addition-Fragmentation chain Transfer (RAFT) agents – organic molecules that can be added to polymerization reactions to precisely control molecular weights and structures of polymers.
Accenture has been ranked as the number one life science information technology (IT) services vendor in a survey conducted by IDC Health Insights.
A York University study has shown for the first time how the drug misoprostol, which has been linked to neurodevelopmental defects associated with autism, interferes with neuronal cell function.
Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product "ATI-1123," a novel and improved formulation of Taxotere® (docetaxel), a leading chemotherapy drug with worldwide annual sales of over $2.8 billion.
› Verified 4 days ago
| Entity Name | Avera St Marys |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669457180 PECOS PAC ID: 0143134965 Enrollment ID: O20040225000579 |
News Archive
Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced it will be presenting data from the Phase 2 clinical trial of their lead drug candidate for postmenopausal symptoms, Menerba, to the international community at the 13th Annual World Congress on Menopause in Rome, Italy on June 11, 2011.
Sigma-Aldrich (Nasdaq: SIAL) announced today that it has entered into a worldwide licensing agreement with Australia's Commonwealth Scientific and Industrial Research Organization (CSIRO) to manufacture and sell Reversible Addition-Fragmentation chain Transfer (RAFT) agents – organic molecules that can be added to polymerization reactions to precisely control molecular weights and structures of polymers.
Accenture has been ranked as the number one life science information technology (IT) services vendor in a survey conducted by IDC Health Insights.
A York University study has shown for the first time how the drug misoprostol, which has been linked to neurodevelopmental defects associated with autism, interferes with neuronal cell function.
Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product "ATI-1123," a novel and improved formulation of Taxotere® (docetaxel), a leading chemotherapy drug with worldwide annual sales of over $2.8 billion.
› Verified 4 days ago
| Entity Name | Black Hills Surgical Hospital Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972630275 PECOS PAC ID: 5496742835 Enrollment ID: O20050616000485 |
News Archive
Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced it will be presenting data from the Phase 2 clinical trial of their lead drug candidate for postmenopausal symptoms, Menerba, to the international community at the 13th Annual World Congress on Menopause in Rome, Italy on June 11, 2011.
Sigma-Aldrich (Nasdaq: SIAL) announced today that it has entered into a worldwide licensing agreement with Australia's Commonwealth Scientific and Industrial Research Organization (CSIRO) to manufacture and sell Reversible Addition-Fragmentation chain Transfer (RAFT) agents – organic molecules that can be added to polymerization reactions to precisely control molecular weights and structures of polymers.
Accenture has been ranked as the number one life science information technology (IT) services vendor in a survey conducted by IDC Health Insights.
A York University study has shown for the first time how the drug misoprostol, which has been linked to neurodevelopmental defects associated with autism, interferes with neuronal cell function.
Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product "ATI-1123," a novel and improved formulation of Taxotere® (docetaxel), a leading chemotherapy drug with worldwide annual sales of over $2.8 billion.
› Verified 4 days ago
| Entity Name | Monument Health Rapid City Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275553463 PECOS PAC ID: 6002729506 Enrollment ID: O20070625000144 |
News Archive
Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced it will be presenting data from the Phase 2 clinical trial of their lead drug candidate for postmenopausal symptoms, Menerba, to the international community at the 13th Annual World Congress on Menopause in Rome, Italy on June 11, 2011.
Sigma-Aldrich (Nasdaq: SIAL) announced today that it has entered into a worldwide licensing agreement with Australia's Commonwealth Scientific and Industrial Research Organization (CSIRO) to manufacture and sell Reversible Addition-Fragmentation chain Transfer (RAFT) agents – organic molecules that can be added to polymerization reactions to precisely control molecular weights and structures of polymers.
Accenture has been ranked as the number one life science information technology (IT) services vendor in a survey conducted by IDC Health Insights.
A York University study has shown for the first time how the drug misoprostol, which has been linked to neurodevelopmental defects associated with autism, interferes with neuronal cell function.
Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product "ATI-1123," a novel and improved formulation of Taxotere® (docetaxel), a leading chemotherapy drug with worldwide annual sales of over $2.8 billion.
› Verified 4 days ago
| Entity Name | Black Hills Surgical Hospital Llp |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1376896621 PECOS PAC ID: 5496742835 Enrollment ID: O20130513000380 |
News Archive
Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced it will be presenting data from the Phase 2 clinical trial of their lead drug candidate for postmenopausal symptoms, Menerba, to the international community at the 13th Annual World Congress on Menopause in Rome, Italy on June 11, 2011.
Sigma-Aldrich (Nasdaq: SIAL) announced today that it has entered into a worldwide licensing agreement with Australia's Commonwealth Scientific and Industrial Research Organization (CSIRO) to manufacture and sell Reversible Addition-Fragmentation chain Transfer (RAFT) agents – organic molecules that can be added to polymerization reactions to precisely control molecular weights and structures of polymers.
Accenture has been ranked as the number one life science information technology (IT) services vendor in a survey conducted by IDC Health Insights.
A York University study has shown for the first time how the drug misoprostol, which has been linked to neurodevelopmental defects associated with autism, interferes with neuronal cell function.
Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product "ATI-1123," a novel and improved formulation of Taxotere® (docetaxel), a leading chemotherapy drug with worldwide annual sales of over $2.8 billion.
› Verified 4 days ago
| Entity Name | Peloton Anesthesia Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912596545 PECOS PAC ID: 7911312178 Enrollment ID: O20210219002480 |
News Archive
Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced it will be presenting data from the Phase 2 clinical trial of their lead drug candidate for postmenopausal symptoms, Menerba, to the international community at the 13th Annual World Congress on Menopause in Rome, Italy on June 11, 2011.
Sigma-Aldrich (Nasdaq: SIAL) announced today that it has entered into a worldwide licensing agreement with Australia's Commonwealth Scientific and Industrial Research Organization (CSIRO) to manufacture and sell Reversible Addition-Fragmentation chain Transfer (RAFT) agents – organic molecules that can be added to polymerization reactions to precisely control molecular weights and structures of polymers.
Accenture has been ranked as the number one life science information technology (IT) services vendor in a survey conducted by IDC Health Insights.
A York University study has shown for the first time how the drug misoprostol, which has been linked to neurodevelopmental defects associated with autism, interferes with neuronal cell function.
Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product "ATI-1123," a novel and improved formulation of Taxotere® (docetaxel), a leading chemotherapy drug with worldwide annual sales of over $2.8 billion.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Peter C Glassbrenner, 353 Fairmont Blvd, Atten Christie Mss, Rapid City, SD 57701-7350 Ph: () - | Peter C Glassbrenner, 353 Fairmont Blvd, Rapid City, SD 57701-7350 Ph: (605) 719-1000 |
News Archive
Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced it will be presenting data from the Phase 2 clinical trial of their lead drug candidate for postmenopausal symptoms, Menerba, to the international community at the 13th Annual World Congress on Menopause in Rome, Italy on June 11, 2011.
Sigma-Aldrich (Nasdaq: SIAL) announced today that it has entered into a worldwide licensing agreement with Australia's Commonwealth Scientific and Industrial Research Organization (CSIRO) to manufacture and sell Reversible Addition-Fragmentation chain Transfer (RAFT) agents – organic molecules that can be added to polymerization reactions to precisely control molecular weights and structures of polymers.
Accenture has been ranked as the number one life science information technology (IT) services vendor in a survey conducted by IDC Health Insights.
A York University study has shown for the first time how the drug misoprostol, which has been linked to neurodevelopmental defects associated with autism, interferes with neuronal cell function.
Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product "ATI-1123," a novel and improved formulation of Taxotere® (docetaxel), a leading chemotherapy drug with worldwide annual sales of over $2.8 billion.
› Verified 4 days ago
Dawn Jo Zastoupil, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 353 Fairmont Blvd, Rapid City, SD 57501 Phone: 605-755-1000 | |
Patrick Staedtler, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 353 Fairmont Blvd, Rapid City, SD 57701 Phone: 605-755-1000 | |
Joseph W Amo, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 353 Fairmont Blvd, Rapid City, SD 57701 Phone: 605-719-1000 | |
Jessica Anne Newman, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 353 Fairmont Blvd, Rapid City, SD 57701 Phone: 605-719-1000 | |
Karen A Bryant, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 353 Fairmont Blvd., Rapid City, SD 57701 Phone: 605-719-1000 | |
Mr. Peter Schwiesow, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 216 Anamaria Dr, Rapid City, SD 57701 Phone: 606-721-4700 | |
Katie Kristine Bates, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 353 Fairmont Blvd, Rapid City, SD 57701 Phone: 605-719-1000 Fax: 605-719-7884 |